UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

January 31, 2013

--------------------------------------------

Date of Report (Date of earliest event reported) 

ELITE PHARMACEUTICALS INC.

--------------------------------------------------------

(Exact name of registrant as specified in its charter)

165 Ludlow Avenue, Northvale NJ 07647

------------------------------------------------------------------

(Address of principal executive offices)

(201) 750-2646

---------------------------

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On January 31, 2013, the Company received a letter from the US Food and Drug Administration approving the supplement filed by the Company with the agency to change the manufacturing location of the naltrexone hydrochloride tablets, 50 mg ANDA to the Company’s facility.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

d) Exhibits

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.